Urinary symptoms as for ICIQ- FLUTS questionnaire in Pulmonary Tuberculosis in Adolescent Girls

Sharma S1, Sharma J2

Research Type

Clinical

Abstract Category

Paediatrics

Abstract 546
Open Discussion ePosters
Scientific Open Discussion Session 21
Thursday 28th September 2023
15:15 - 15:20 (ePoster Station 1)
Exhibit Hall
Urgency Urinary Incontinence Infection, other Quality of Life (QoL)
1. National Institute of Tuberculosis and Respiratory Diseases New Delhi, 2. AIIMS New Delhi
Presenter
Links

Abstract

Hypothesis / aims of study
Tuberculosis remains a major public health problem globally. It is chronic infectious disease due to Mycobacterium tuberculous (rarely Mycobacterium bovis from unpasteurized infected milk).  Each year, an estimated 1.8 million adolescents (aged 10–19 years) and young adults (aged 20–24 years) become sick with tuberculosis (TB), representing approximately 18% of the annual global TB incidence. Although it is preventable and treatable, TB is a leading cause of death among adolescents and young adults (AYAs) globally. The World Health Organization (WHO) estimates that in 2019, 71,000 adolescents (11,000 between 10 and 14 years of age and 60,000 between the ages of 15 and 19 years) and 90,000 young adults died of TB. Tuberculosis can also involve other organs including urogenital system or can itself cause urinary symptoms. To study the prevalence of various urinary symptoms as per ICIQ FLUTS questionnaire in pulmonary tuberculosis in adolescent girls
Study design, materials and methods
It’s a prospective study on total of 100 cases in pulmonary tuberculosis in adolescent girls over 6 month’s period. They were interrogated for various urinary symptoms per ICIQ- FLUTS (International Consultation on Incontinence Questionnaire) questionnaire which is a validated questionnaire for evaluating female lower urinary tract symptoms and impact on quality of life. In this questionnaire, patients are asked about the exposure of 12 specific urinary symptoms with scoring of 0 to 4 for urinary symptoms and 0 to 10 for effect on quality of life. Descriptive statistics such as mean, median, standard deviation and range values were calculated for study characteristics like age, body mass index and duration of symptoms. Continuous variables were tested for normality assumptions using Kolmogrov Smirnov tests, Chi square test or Fisher’s exact test was used for frequencies of categorical variations. A two tailed probability level with p<0.05 was considered for statistical significance. All data analysis were carried out using IBM SPSS statistics for windows version 19.0 New York IBM Corp.
Results
The mean age and body mass in index was 14.1± 2.8 year and 19.8+2.8 Kg/mg2. All patients had drug sensitive pulmonary tuberculosis. A total of 8 percent patients had noctoria with 2% getting ups 3 and 1% getting 4 times or more in the night. Sudden need to rush to toilet was seen in 2%. Bladder pain was seen in 15% (occasional in 2%, some-times in 13%) patients. Delay in starting urination and straining to urinate was seen in 2% and 6% cases respectively. Stress urinary incontinence was seen 9% cases, while leaking without obvious cause was seen in 8% cases. A total of 3% cases had noctural enuresis. A total of 3% patients to stopped and started urination more than once while 4% had urge incontinenc which was sometime and 3% patient had 2.3 times leaking per week. One of the cases had associated genitourinary tuberculosis with hematuria. All patients of stress urinary incontinence and other urinary symptoms were treated with pelvic floor exercises, life style modifications, Yoga therapy while patients with urge incontinence were given anticholinergic drugs (Darifenacin 7.5 mg once  daily for 3 months).
Interpretation of results
ICIQ- FLUTS questionnaire has showed high prevalence in pulmonary tuberculosis adolescent girls.
Concluding message
There is high prevalence of urinary symptoms on ICIQ- FLUTS questionnaire in pulmonary tuberculosis adolescent girls.  Timely diagnosis and treatment can improve the symptoms.
Disclosures
Funding yes Clinical Trial Yes
28/04/2025 13:15:55